A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Cyclizine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. |
| Hydrocodone | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Cyclizine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Cyclizine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. |
| Mirtazapine | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. |
| Orphenadrine | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. |
| Pramipexole | Cyclizine may increase the sedative activities of Pramipexole. |
| Ropinirole | Cyclizine may increase the sedative activities of Ropinirole. |
| Rotigotine | Cyclizine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Cyclizine. |
| Sodium oxybate | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. |
| Thalidomide | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Cyclizine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Cyclizine. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cyclizine. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cyclizine. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyclizine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Cyclizine. |
| Ethanol | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Cyclizine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Cyclizine is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Cyclizine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Cyclizine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Cyclizine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Cyclizine is combined with Alaproclate. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Citalopram. |
| Escitalopram | The risk or severity of adverse effects can be increased when Cyclizine is combined with Escitalopram. |
| Amphetamine | Amphetamine may decrease the sedative activities of Cyclizine. |
| Phentermine | Phentermine may decrease the sedative activities of Cyclizine. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Cyclizine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Cyclizine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Cyclizine. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Cyclizine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Cyclizine. |
| MMDA | MMDA may decrease the sedative activities of Cyclizine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Cyclizine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cyclizine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cyclizine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Cyclizine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Cyclizine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Cyclizine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Cyclizine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Cyclizine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Cyclizine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Cyclizine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Cyclizine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Cyclizine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Cyclizine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Cyclizine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Cyclizine. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Cyclizine. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Cyclizine. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Cyclizine. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Cyclizine. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Cyclizine. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Cyclizine. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Cyclizine. |
| Nicardipine | The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Cyclizine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Cyclizine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Cyclizine. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Cyclizine. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Solifenacin. |
| Pizotifen | The risk or severity of CNS depression can be increased when Cyclizine is combined with Pizotifen. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Trimebutine. |
| Dosulepin | The risk or severity of CNS depression can be increased when Cyclizine is combined with Dosulepin. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Quinidine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Cyclizine is combined with Zopiclone. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Leuprolide. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Goserelin. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Azithromycin. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Moxifloxacin. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ranolazine. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Sulfisoxazole. |
| Diltiazem | The metabolism of Diltiazem can be decreased when combined with Cyclizine. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Nimodipine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Cyclizine. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ciprofloxacin. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Fluorouracil. |